Shares of Sionna Therapeutics (SION) surged 38.89% in its trading debut on Friday, buoyed by investor enthusiasm for the clinical-stage biopharmaceutical company's successful initial public offering (IPO).
Sionna, which is developing drugs to treat cystic fibrosis, sold 10.6 million shares at $18 per share in its upsized IPO, raising $191 million. The IPO was priced at the top end of its expected range, reflecting strong investor demand for the company's shares.
Based in Waltham, Massachusetts, Sionna is vying for a share of the lucrative cystic fibrosis market, currently dominated by Vertex Pharmaceuticals. The company aims to leverage its expertise in cystic fibrosis therapeutics to develop innovative treatments for the disease.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。